Literature DB >> 15705794

Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases.

Mingjiang Xu1, Edward Bruno, Joseph Chao, Stephen Huang, Guido Finazzi, Steven M Fruchtman, Uday Popat, Josef T Prchal, Giovanni Barosi, Ronald Hoffman.   

Abstract

Idiopathic myelofibrosis (IM) is characterized by increased numbers of CD34(+) cells in the peripheral blood (PB). We explored the possible mechanisms underlying this abnormal trafficking of CD34(+) cells. Plasma levels of neutrophil elastase (NE), total and active matrix metalloproteinase 9 (MMP-9), and soluble vascular cell adhesion molecule-1 (sVCAM-1) were dramatically increased in IM. The absolute number of CD34(+) cells in the PB was correlated with the levels of sVCAM-1. Marked elevations of the levels of NE but not total and active MMP-9 as well as MMP-2 were detected in media conditioned by IM mononuclear cells (MNCs) as compared with that of healthy volunteers. IM MNC-conditioned media, however, was shown by zymographic analysis to contain increased gelatinolytic activity corresponding to the molecular weight of MMP-9. IM MNC-conditioned media also exhibited a greater ability to cleave VCAM-1 and c-kit in vitro, consistent with the biologic actions of NE. In addition, the increased ability of IM PB CD34(+) cells to migrate through a reconstituted basement membrane was diminished by several inhibitors of MMP-9 activity, indicating that these cells express increased levels of this MMP. These data indicate that a proteolytic environment exists in IM which might result in the sustained mobilization of CD34(+) cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15705794     DOI: 10.1182/blood-2004-08-3238

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

Review 1.  Neutrophil serine proteases fine-tune the inflammatory response.

Authors:  Christine T N Pham
Journal:  Int J Biochem Cell Biol       Date:  2007-11-29       Impact factor: 5.085

2.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

3.  Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents.

Authors:  Xiaoli Wang; Wei Zhang; Takefumi Ishii; Selcuk Sozer; Jiapeng Wang; Mingjiang Xu; Ronald Hoffman
Journal:  Cancer Res       Date:  2009-09-14       Impact factor: 12.701

4.  Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status.

Authors:  Oliver Bock; Johanne Neuse; Kais Hussein; Kai Brakensiek; Guntram Buesche; Thomas Buhr; Birgitt Wiese; Hans Kreipe
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

5.  Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.

Authors:  Christina Hart; Sabine Klatt; Johann Barop; Gunnar Müller; Roland Schelker; Ernst Holler; Elisabeth Huber; Wolfgang Herr; Jochen Grassinger
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

6.  Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis.

Authors:  Stefan O Ciurea; Delwin Merchant; Nadim Mahmud; Takefumi Ishii; Yan Zhao; Wenyang Hu; Edward Bruno; Giovanni Barosi; Mingjiang Xu; Ronald Hoffman
Journal:  Blood       Date:  2007-05-01       Impact factor: 22.113

7.  Release of matrix metalloproteinase-8 during physiological trafficking and induced mobilization of human hematopoietic stem cells.

Authors:  Carolin Steinl; Mike Essl; Thomas D Schreiber; Konstanze Geiger; Lea Prokop; Stefan Stevanović; Oliver Pötz; Harald Abele; Johannes T Wessels; Wilhelm K Aicher; Gerd Klein
Journal:  Stem Cells Dev       Date:  2013-02-12       Impact factor: 3.272

8.  Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease.

Authors:  Anna Rita Migliaccio; Fabrizio Martelli; Maria Verrucci; Giovanni Migliaccio; Alessandro Maria Vannucchi; Hongyu Ni; Mingjiang Xu; Yi Jiang; Betty Nakamoto; Thalia Papayannopoulou; Ronald Hoffman
Journal:  Exp Hematol       Date:  2008-02       Impact factor: 3.084

9.  Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.

Authors:  Mohamad Bassam Sonbol; Belal Firwana; Ahmad Zarzour; Mohammad Morad; Vishal Rana; Ramon V Tiu
Journal:  Ther Adv Hematol       Date:  2013-02

10.  Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines.

Authors:  Oliver Bock; Julia Höftmann; Katharina Theophile; Kais Hussein; Birgitt Wiese; Jerome Schlué; Hans Kreipe
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.